Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-5ALA-PDT for NMIBC Recurrence Prevention
NCT05547516Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of 5-aminolevulinic acid in Non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Tumor recurrence rate 1 year after surgery. Status: unknown.
02
Drugs
5-aminolevulinic acid
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05547516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547516.